Showing 1 to 10 of 37 Clinical Trials
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
---|---|---|---|
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
MK-2140-006 NCT05458297 Recruiting |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma |
Dr. Sarit Assouline Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
MK-1026-003 NCT04728893 Recruiting |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX |
Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Nawel Mechtouf 514-252-3400 poste 4681 |
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCIC GEC LY.17 NCT02436707 Recruiting |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non-Hodgkin's Lymphoma |
Dr. Stéphane Doucet Chantal Gosselin 514-890-8000 poste 24892 |
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCIC GEC LY.17 NCT02436707 Recruiting |
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS |
Non-Hodgkin's Lymphoma |
Dr. Jean-François Larouche Marie-Claude Bourgeois 418-649-0252 poste 63161 |
A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases
EBV-TCL-01 NCT02580539 Recruiting |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX |
Non-Hodgkin's Lymphoma |
Dr. Jean-Sébastien Delisle Stéphanie Thiant 514-252-3400 poste 4681 |
Un registre de données cliniques et paracliniques, incluant une banque de tissus biologiques, de patients atteints d’un lymphome (Registre des lymphomes)
HMR-LYM001 Recruiting |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX |
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Michel-Olivier Gratton 514-252-3400 poste 2397 |
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma
TAC01-CD19-01 NCT03880279 Recruiting |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX |
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Michel-Olivier Gratton 514-252-3400 poste 2397 |
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma
EPCORE FL-1 NCT05409066 Recruiting |
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI |
Non-Hodgkin's Lymphoma |
Dr. Samuel Nadeau Isabelle Gagnon 418-724-3000 poste 8029 |
A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
POLARGO NCT04182204 Recruiting |
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR |
Non-Hodgkin's Lymphoma |
Dr. Jean-Sébastien Aucoin Marie-Ève Caron 819-697-3333 poste 63238 |
A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-1 (EZH-302) NCT04224493 Recruiting |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Non-Hodgkin's Lymphoma |
Dr. Nathalie Johnson |